医疗技术公司Glaukos(GKOS)股价今日盘前大跌11.67%,引发市场广泛关注。
Glaukos公司昨日发布了第四季度财报,数据显示该公司第四季度净亏损扩大至2220万美元,远超市场预期的2080万美元亏损。虽然营收达到1.055亿美元高于市场预期,但仍未能令投资者信心完全恢复。
值得一提的是,Glaukos的主要产品iStent inject W是一种用于治疗青光眼的创新医疗器械,针对一种损害视神经的严重眼病。公司业务发展前景一直备受市场关注,但近期财务数据不佳或许给投资者带来一些负面影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.